Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.

Bank Name Bio-Path Holdings, Inc.
Stock Exchange NASDAQ
Symbol BPTH
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman Mr. Peter H. Nielsen
CEO Mr. Peter H. Nielsen
Employees 9
Registered Year 2007